The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis

Thomas DL (2013) Global control of hepatitis C: where challenge meets opportunity. Nat Med 19(7):850

Jimenez AP, Eldin NS, Rimlinger F, El-Daly M, El-Hariri H, El-Hoseiny M et al (2010) HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut 59(11):1554–1560

Abdel-Aziz F, Habib M, Mohamed MK et al (2000) Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology. 32(1):111–115

El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008. Cairo: Ministry of Health, El-Zanaty and Associates and Macro International; 2009. p. 431.

Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M (2016) The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver international: official journal of the International Association for the Study of the Liver 37(1):45–53

Polo ML, Laufer N (2017) Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Rev Anti-Infect Ther 15(8):737–746

Galossi A, Guarisco R, Bellis L, Puoti C (2007) Extrahepatic manifestations of chronic HCV infection. Journal of Gastrointestinal and Liver Diseases 16(1):65

Cacoub P, Comarmond C. New insights into HCV-related rheumatologic disorders: a review Journal of advanced research 2017; 8(2):89-97.

Silberbogen AK, Janke EA, Hebenstreit C (2007) A closer look at pain and hepatitis C: preliminary data from a veteran population. J Rehabil Res Dev 44(2):231–244

Iagnocco A, Giulio C, Stefania B, Donnarumma L, Guido V, Vincenzo P (2004) Joint sonography in asymptomatic patients with HCV correlated hepatitis. Clin Exp Rheumatol 22(1):43–48

Saadoun D, Thibault V, Ahmed SN, Alric L, Mallet M, Guillaud C et al (2016) Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 75(10):1777–1782

Gota C, Calabrese L (2003) Induction of clinical autoimmune disease by therapeutic interferon-α. Autoimmunity 36(8):511–518

Boonyapisit K, Katirji B (2002) Severe exacerbation of hepatitis C–associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 25(6):909–913

Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR et al (2015) Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 62(5):1040–1046

Gomaa A, Allam N, Elsharkawy A, El Kassas M, Waked I (2017) Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med 9:17–25

Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al (2007) Meta- analysis: diagnostic accuracy of anti–cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146(11):797–808

Kemmer NM, Sherman KE (2010) Hepatitis C-related arthropathy: Diagnostic and treatment considerations. The Journal of musculoskeletal medicine 27(9):351

Lienesch D, Morris R, Metzger A, Debuys P, Sherman K (2005) Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. J Rheumatol 32(3):489–493

Wener MH, Hutchinson K, Morishima C, Gretch DR (2004) Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 50(7):2305–2308

Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48

Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the esophagus for bleeding oesophageal varices. Br J Surg 60:646–649

Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP, Swen WA et al (2001) Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 60:641–649

Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D'Agostino MA et al (2005) Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 32(12):2485–2487

Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS, Ostergaard M (2003) Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum 48:955–962

Scheel AK, Hermann KG, Kahler E, Pasewaldt D, Fritz J, Hamm B et al (2005) Novel ultrasonographic synovitis scoring system suitable for analyzing finger joint inflammation in rheumatoid arthritis. Arthritis Rheum 52:733–743

El-Akel W, El-Sayed MH, El Kassas M, El-Serafy M, Khairy M, Elsaeed K et al (2017) National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. J Viral Hepat 24(4):262–267

Shahin AA, Zayed HS, Said M, Amer SA (2018) Efficacy and safety of sofosbuvir-based, interferon-free therapy. Z Rheumatol 77(7):621–628

Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L et al (2016) Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology 64(5):1473–1482

Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL et al (2016) Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 63(2):408–417

Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M et al (2015) Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 63(3):581–585

Zuckerman E, Keren D, Rozenbaum M, Toubi E, Slobodin G, Tamir A et al (2000) Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol 18(5):579–584

Lovy MR, Starkebaum G, Uberoi S (1996) Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. J Rheumatol 23(6):979–983

Ueno Y, Kinoshita R, Kishimoto I, Okamoto S (1994) Polyarthritis associated with hepatitis C virus infection. Rheumatology 33(3):289–291

Rosner I, Rozenbaum M, Toubi E, Kessel A, Naschitz JE, Zuckerman E (2004) The case for hepatitis C arthritis. Semin Arthritis Rheum 33(6):375–387

Kumthekar A, Shull S, Lovejoy TI, Morasco BJ, Chang M, Barton J (2019) Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis. Int J Rheum Dis 22(4):592–598

Ahmed OA, Elsebaey MA, Fouad MH, Elashry H, Elshafie AI, Elhadidy AA et al (2018) Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infection and drug resistance 11:441